This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Analysts' Actions: BAC, JCP, NTAP

Apple (AAPL) estimates, target were boosted at Sterne Agee. Shares are now seen reaching $750. Estimates were also increased, following channel checks, Sterne Agee. Buy rating.

Ball numbers were raised at Jefferies. Shares are now seen reaching $49. Estimates also raised on favorable rigids volume trends, Jefferies said. Buy rating.

Canadian Pacific Railway (CP) numbers were raised at Jefferies. Shares are now seen reaching $72. Estimates were also raised on first-quarter guidance, Jefferies said. Hold rating.

Forest Labs (FRX) numbers were cut at Credit Suisse. Shares are now seen reaching $44. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating.

First Solar (FSLR) numbers were cut at UBS. Shares are now seen reaching $23. Estimates were also lowered as module business is affecting system value, UBS said. Neutral rating.

Las Vegas Sands (LVS) numbers were increased at BMO Capital. Estimates were raised through 2013. Macau should continue to drive growth, BMO Capital said. Outperform rating and new $69 price target.

Priceline.com (PCLN) numbers were raised at Benchmark. Shares are now seen reaching $840. Estimates were also increased, given better industry trends and emerging market growth, Benchmark said. Buy rating.

Qlik Technologies (QLIK) price target was raised at Jefferies to $35. Survey suggests modest upside risk, Jefferies said. Buy rating.

VMware (VMW) price target was raised at Jefferies to $100. Improved current year growth expectations, Jefferies said. Hold rating.

ViroPharma Incorporated (VPHM) numbers were lowered at Jefferies. Shares are now seen reaching $33. Estimates were also lowered on FDA approval of generic Vancocin, Jefferies said. Buy rating.

ViroPharma Incorporated numbers were lowered at Oppenheimer. Shares are now seen reaching $27. Estimates were also lowered on denial of Citizen's Petition related to Vancocin, Oppenheimer said. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:






Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BAC $16.01 1.26%
JCP $7.85 -7.65%
NTAP $38.58 -0.18%
AAPL $129.09 0.49%
FB $79.75 0.99%

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs